[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100641079":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":26,"centralContacts":30,"locations":36,"responsibleParty":47,"collaborators":25,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":25,"eligibilityCriteria":55,"healthyVolunteers":51,"sex":56,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":25,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":69,"overallStatus":76,"whyStopped":25,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"Pakistan Air Force (PAF) Hospital Islamabad","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Daily Iron","ACTIVE_COMPARATOR","One ferrous sulfate 325 mg tablet (approximately 65 mg elemental iron) once daily for four weeks.",[13],"Drug: Ferrous Sulfate",{"label":15,"type":16,"description":17,"interventionNames":18},"Alternate-Day Iron","EXPERIMENTAL","Two ferrous sulfate 325 mg tablets (approximately 130 mg elemental iron) every other day for four weeks.",[13],[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Ferrous Sulfate","Oral ferrous sulfate 325 mg tablets (approximately 65 mg elemental iron per tablet) administered for four weeks according to the assigned dosing schedule. All participants receive standardized counseling on administration, diet, side effects, and adherence, and are issued a dose diary.",[15,9],null,[27],{"name":28,"affiliation":5,"role":29},"Ammara Suleman, MBBS","PRINCIPAL_INVESTIGATOR",[31],{"name":32,"role":33,"phone":34,"phoneExt":25,"email":35},"Ammara Suleman","CONTACT","+92 321 5279502","shazibnawaz2016@gmail.com",[37],{"facility":5,"status":25,"city":38,"state":25,"zip":25,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":25},"Islamabad","Pakistan","PK",{"type":42,"coordinates":43},"Point",[44,45],73.04329,33.72148,{"lat":45,"lon":44},{"type":29,"investigatorFullName":32,"investigatorTitle":48,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"Principal Investigator","100641079","daily-versus-alternate-day-oral-iron-therapy-for-anemia-in-second-trimester-pregnancy-100641079",false,"NCT07657455","Daily Versus Alternate-Day Oral Iron Therapy for Anemia in Second-Trimester Pregnancy","Daily Versus Alternate-Day Oral Iron Therapy for Anemia Correction in Second-Trimester Pregnant Patients: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Aged 18 to 40 years\n* Pregnant women in the second trimester (13 to 27 weeks gestation)\n* Hemoglobin below 11 g\u002FdL with serum ferritin below 30 ng\u002FmL\n* Singleton pregnancy\n\nExclusion Criteria:\n\n* Known congenital or acquired hemoglobin disorders (e.g., thalassemia, hemoglobinopathies)\n* Chronic diseases affecting hemoglobin levels (e.g., chronic kidney disease, inflammatory disorders)\n* Bleeding disorders or a history of frequent blood loss\n* Gastrointestinal conditions impairing nutrient absorption (e.g., celiac disease or other malabsorption syndromes)\n* Currently receiving parenteral iron\n* Requiring blood transfusion","FEMALE","18 Years","40 Years",{"count":60,"type":61},184,"ESTIMATED","INTERVENTIONAL",[64],"NA","This randomized controlled trial compares daily versus alternate-day oral iron supplementation in pregnant women with iron deficiency anemia during the second trimester. The study evaluates changes in hemoglobin and serum ferritin, treatment adherence, and gastrointestinal side effects to inform more patient-centered, physiologically aligned dosing strategies.",[67,68],"Iron Deficiency Anemia","Anemia in Pregnancy",[70,71,72,73,74,75],"oral iron","ferrous sulfate","alternate-day dosing","hepcidin","second trimester","adherence","NOT_YET_RECRUITING","2026-06-14",{"date":79,"type":80},"2026-06-18","ACTUAL",{"date":82,"type":61},"2026-09",{"date":84,"type":61},"2027-02",{"name":5,"class":6},1]